The two articles “A Spike in Rates of Pregnancy-related Deaths in Texas Spurs Soul-searching” by Nina Martin and “Now There’s Proof: Docs Who Get Company Cash Tend to Prescribe More Brand-Name Meds” by Charles Orstein et. al share a unique connection beyond their health-care-related focus, they both discuss outcomes regarding treatment after significant changes in payment. In the former article, the issue seems to be pay cuts as maternal mortality in Texas skyrockets after cuts to Planned Parenthood, however, the author offers another biologic explanation “…cardiac problems. The second leading cause: drug overdoses. Hemorrhages and blood transfusion were the biggest factors associated with severe complications.” The author mentions that the
…show more content…
The current is a step ahead of the previous study that monitored the payouts of 5 pharmaceutical companies through the Physician Payment Sunshine Act and the 2010 Affordable Care Act with dating ending last year. The population for this study was selected for under the conditions that the doctor writes at least 1,000 prescriptions in Medicare Part D under the premise that brand-name drug use would have a major effect on Medicare as a payer this leads to a large sample size as Medicare takes care of 39 million people in the country. However, there contentions against these sampling conditions, in the article Dr. David W. Parke II state that payments from pharmaceutical companies do not always directly translate to prescription practices, but also possibly prosthetics or new devices, meaning that it would “be unfair to presume that industry payments are associated with prescribing in Part D.” Dr. Kim Allan William Sr., also mentioned in the article, states that there might be a circular, unintentional relationship between industry payouts, brand-name prescriptions, and career success, especially in cardiology. It is possible that more accurate parameters for industry payouts and prescription practices may exist than those posed in this …show more content…
Especially in the case of the first article by Nina Martin where the Texas Task force failed to come up with a rate and identified fewer maternal mortality cases over time, suggesting a decreasing trend. Not considering that the Texas Taskforce did not even bother to study whether the family planning cuts had any effect on their data or mortality when these cuts could easily be a confounding factor that Boston University attributed for. This calls into questions their other values, like the statement that Latina Women do not suffer egregiously from maternal mortality because their maternal deaths rate is lower than that of African Americans, we wonder if this statement will hold true when adjusted for resources or socioeconomic status. The study lacks specificity without proper attention to what parameters should define the population, and inherently without this specificity, it may seem that your conclusions may seem purposefully generalized - and even
The current is a step ahead of the previous study that monitored the payouts of 5 pharmaceutical companies through the Physician Payment Sunshine Act and the 2010 Affordable Care Act with dating ending last year. The population for this study was selected for under the conditions that the doctor writes at least 1,000 prescriptions in Medicare Part D under the premise that brand-name drug use would have a major effect on Medicare as a payer this leads to a large sample size as Medicare takes care of 39 million people in the country. However, there contentions against these sampling conditions, in the article Dr. David W. Parke II state that payments from pharmaceutical companies do not always directly translate to prescription practices, but also possibly prosthetics or new devices, meaning that it would “be unfair to presume that industry payments are associated with prescribing in Part D.” Dr. Kim Allan William Sr., also mentioned in the article, states that there might be a circular, unintentional relationship between industry payouts, brand-name prescriptions, and career success, especially in cardiology. It is possible that more accurate parameters for industry payouts and prescription practices may exist than those posed in this …show more content…
Especially in the case of the first article by Nina Martin where the Texas Task force failed to come up with a rate and identified fewer maternal mortality cases over time, suggesting a decreasing trend. Not considering that the Texas Taskforce did not even bother to study whether the family planning cuts had any effect on their data or mortality when these cuts could easily be a confounding factor that Boston University attributed for. This calls into questions their other values, like the statement that Latina Women do not suffer egregiously from maternal mortality because their maternal deaths rate is lower than that of African Americans, we wonder if this statement will hold true when adjusted for resources or socioeconomic status. The study lacks specificity without proper attention to what parameters should define the population, and inherently without this specificity, it may seem that your conclusions may seem purposefully generalized - and even